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ABSTRACT 
Objective: Buccal patch is a non-dissolving thin matrix modified release dosage form which was developed to administer into the unconscious and 
less co-operative patients.  
Methods: The mucoadhesive buccal patches of hydrochlorothiazide (HCZ) and atenolol (ATN) were prepared by solvent casting technique using 
various concentrations of sodium alginate, hydroxyl propyl methyl cellulose, carbopol 934P and sodium carboxy methyl cellulose polymer and 
polyvinyl alcohol as a backing layer. The formulated patches were evaluated for their physicochemical parameters like thickness, weight variation, 
surface pH, content uniformity, folding endurance, swelling percentage studies and tensile strength, in vitro and ex vivo drug permeation.  
Results: The infra-red (IR) spectra showed no interaction between drug and polymer. Physicochemical characteristics of all the samples were found 
to be satisfactory and well within the range. Swelling of the films were increased with the increasing content of the polymers and it was found that 
swelling front erosion was comparably slower in the formulations with the carbopol 934 and HPMC. This is probably due to their marked viscous 
properties and therefore formulation provided sustained release of the drug. The percentage drug content of all the formulations were found to be 
in the range of 97-99 %. Among the patches, FC (Carbopol 934 and HPMC) patches were considered satisfactory for maintaining the in vitro 
residence in the oral cavity for almost 8h. Formulations FD (with CP and NaCMC) and FC showed high tensile strength and % E/B which is an 
indication of the strength and elasticity of the patch. The films were exhibited sustained release for more than 6 h which was confirmed by the in 
vitro release data and kinetic data reveals the combination of diffusion and erosion mechanism. The best mucoadhesive performance and matrix 
controlled release was exhibited by the formulation FC.  
Conclusion: The formulation of HCZ and ATN mucoadhesive buccal patch was found to be satisfactory and reasonable. 
Keywords: Buccal mucosa, Solvent casting method, HPMC, Hydrochlorothiazide, Atenolol, Mucoadhesive buccal patches  




Mucoadhesive polymers are synthetic or natural macromolecules which 
are capable of attaching to mucosal surfaces. Mucoadhesive drug 
delivery system has been accepted as a promising strategy to prolong 
the residence time and to improve the specific localization of drug on 
various membranes. Amongst the various routes of drug delivery, the 
oral route is perhaps the most preferred to the patient and the clinician 
alike [1]. However, peroral administration of drugs has disadvantages 
such as hepatic first pass metabolism and enzymatic degradation within 
the GI tract, that prohibit oral administration of certain classes of drugs 
especially peptides and proteins. Consequently, other absorptive 
mucosae are considered as potential sites for drug administration. 
Transmucosal routes of drug delivery (i.e., the mucosal linings of the 
nasal, rectal, vaginal, ocular, and oral cavity) offer distinct advantages 
over per oral administration for systemic drug delivery. These 
advantages include a possible bypass of first pass effect, avoidance of 
pre-systemic elimination within the GI tract, and, also provides a better 
enzymatic flora for drug absorption. Most of the antihypertensive 
formulations are available in the market are in the form of tablets. Most 
of them do present varying degree of disadvantages in terms of efficacy, 
absorption and bioavailability and sometimes show undesirable side 
effects due to fluctuating plasma drug level [2, 3]. 
The effort was made here to formulate the combination of HCZ and 
ATN as a buccal patch to provide sustained release of drug and to 
bypass hepatic first-pass metabolism during the treatment of 
hypertension. HCZ has a half-life of 5-6 h, bioavailability is around 
70 % and classified as BCS class 4 systems. It is mainly eliminated by 
the kidney and its protein binding is approximately 70 %. On the 
other hand, ATN has a half-life of 6-7 h. Duration of action is found to 
be 24 h (once daily dosing). Absorption of the drug is found to be 
absorbed slowly and incompletely from GI tract (oral) and peak 
plasma concentration is achieved after 7 h. The bioavailability of 
ATN is around 25 %. The combination of ATN and HCZ is available in 
the market as tablets, for the treatment of hypertension. 
Hence, buccal patches containing the combination of HCZ and ATN 
was designed and evaluated. 
MATERIALS AND METHODS 
Materials 
Hydrochlorothiazide and Atenolol were procured by Yarrow Chem. 
Pvt. Ltd. polyvinyl alcohol, polyvinylpyrrolidone, ethyl cellulose, 
hydroxy propyl methyl cellulose, sodium alginate and carbopol 934 
were procured by CDH laboratory Reagent, New Delhi. All other 




Compatibility of HCZ and ATN with the excipients was confirmed by 
FTIR studies. The pure drugs, HCZ and ATN with the polymers in the 
ratio of 1:1 were taken and the potassium bromide disc (pellet) 
method was employed to conduct the study. After collecting an 
interferogram of a sample containing pure HCZ and ATN and drugs 
with the polymers, FTIR spectroscopic analysis was performed on 
the interferogram to obtain the spectrum.  
Method of preparation 
A series of buccal patches composed of different proportions and 
combinations of sodium alginate (SA) (100 to 300 mg), 
hydroxypropyl methyl cellulose (HPMC) (200 to 400 mg), carbopol 
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(CP) 934 P (100 to 300 mg), and sodium carboxy methyl cellulose 
(NaCMC) (200 to 400 mg) containing ATN (200 mg) and HCZ (200 
mg) were prepared using a 64 cm2 petri dish by solvent casting 
technique. Glycerine was incorporated as a plasticizer at a 
concentration of 15 % w/w of dry weight of polymers. Backing 
membrane was casted by pouring 4 % w/v aqueous solution of PVA 
on aluminium foil in petri dishes at 42 °C and left for 10 h. Phosphate 
buffer saline, pH 6.8, was used as solvent in the casting method. 200 
mg of ATN and 200 mg of HCZ were incorporated in mixtures 
containing different ratios and combinations of polymers and 
plasticizer. The matrices were prepared by pouring 10 ml of the 
homogeneous solutions on the PVA-aluminium foil backing 
membrane. Then, these buccal patches were dried at 42 °C in an 
incubator (Yorco International Pvt. Ltd., India). After 24 h, the dried 
patches were removed from the petri dishes and kept in desiccators 
until use [4]. The patches were cut into 2 × 2 cm2 and 1×1 cm2 for 
evaluation of the patches. Each patch size of 2 × 2 cm2 contains 3.12 
mg ATN and 3.12 mg HCZ respectively [4]. 
 
Table 1: Composition of different buccal patches 
Ingredients FA FB FC FD 
1 2 3 1 2 3 1 2 3 1 2 3 
HCZ (mg) 200 200 200 200 200 200 200 200 200 200 200 200 
ATN(mg) 200 200 200 200 200 200 200 200 200 200 200 200 
SA (mg) 300 200 100 - - - - - - - - - 
HPMC (mg) 200 300 400 - - - 200  300 400 300  200 100 
Carbopol 934 (mg) - - - 300  200 100 300  200 100 - - - 
NaCMC (mg) - - - 200  300 400 - - - 200  300 400 
Glycerine (%) 15 15 15 15 15 15 15 15 15 15 15 15 
Distilled Water (ml) 40 40 40 40 40 40 40 40 40 40 40 40 
F-formulation, HCZ-hydrochlorothiazide, ATN-atenolol, SA-sodium alginate, HPMC-hydroxymethyl cellulose, NaCMC-sodium carboxymethyl cellulose 
 
Evaluation of buccal patches  
Uniformity of weight 
Ten patches of 1 cm2 were weighed individually and average of 
those patches measured [5]. 
Patch thickness 
The thickness of each patch was measured using screw gauge at five 
different positions of the patch and the average was calculated. 
Folding endurance 
Folding endurance of the patches was determined by repeatedly 
folding one patch at the same place till it broke or folded up to 300 
times manually, which was considered satisfactory to reveal good 
patch properties. The number of times of patch could be folded at 
the same place without breaking gave the value of the folding 
endurance. This test was done on five patches [6]. 
Surface pH of the buccal patches 
The surface pH of the patches was determined to investigate the 
possibility of any side effects due to change in pH in vivo, since an 
acidic or alkaline pH may cause irritation to the buccal mucosa. The 
patch to be tested was placed in petri dish and was moistened with 
0.5 ml of distilled water and kept for 30s. The pH was noted after 
bringing an electrode of PH meter in contact with the surface of the 
formulation and allowing equilibrating for 1 min [6]. 
Measurement of bioadhesive strength 
Bioadhesive strength refers to mechanical strength of the system. 
Bioadhesive strength test was conducted to check the residence time 
of the patch at the site of application. The tensile strength required 
to detach the bioadhesive patch from the mucosal surface was 
reported as a parameter of the bioadhesive performance. In the 
present work, a specially designed or fabricated assembly based on 
published literature was used. Porcine cheek pouch was used as a 
model surface for bioadhesion testing. After the cheek pouch was 
excised and trimmed evenly, it was then washed in simulated 
salivary fluid, and then used immediately [7]. 
Swelling index 
The swelling index procedure was used to determine the general 
swelling characteristics of patch. A drug-loaded patch of 1×1 cm2 
was weighed on a pre-weighed cover slip. It was kept in a petridish 
and 50 ml of phosphate buffer, pH 6.8 was added. After every five 
min, the cover slip was removed and weighed up to 30 min. The 
difference in the weights gives the weight increase due to absorption 
of water and swelling of patch. Area increase due to swelling: A drug 
loaded patch size of 1×1 cm2 was cut and placed in a petridish. A 
graph paper was placed beneath the petridish, to measure the 
increase in the area. Fifty ml of phosphate buffer, pH 6.6, was poured 
into the petridish. An increase in the length and breadth of the patch 
was noted at five min intervals for 60 min and the area was 
calculated. [8] The swelling index was calculated using the following 
equation:  
 
Where, Wt is weight of the patch at time t and W0 is weight of the 
patch at time zero. 
Drug content 
Prepared buccal patch was dissolved in 100 ml of Phosphate buffer 
solution (PBS) of pH 6.8 using a magnetic stirrer for 12 h and then 
sonicated for 30 min designed to contain each 200 mg of HCZ and 
ATN. After filtration to remove insoluble residue, 1 ml of filtrate was 
diluted to 10 ml with phosphate buffer pH 6.8. The absorbance was 
measured at 269.6 nm and 237.3 nm respectively for HCZ and ATN 
using UV spectrophotometer. The percentage drug content of all 
formulations was found to be in the range of 97-99 % [7, 8]. 
Measurement of tensile strength (TS) and Percentage 
elongation (E/B) 
The mechanical property was evaluated using instron universal 
testing instrument (Model 1121, instron Ltd., japan, NITK, Surathkal, 
India) with a 5 kg load cell. Film strips in special dimension and free 
from air bubbles or physical imperfections were held between two 
clamps positioned at a distance of 3 cm. During the measurement, 
the strips were pulled by the top clamp at a rate of 100 mm/min, 
and then the force and elongation were measured when the film 
broke. Results from the film samples, which broke at and not 
between the clamps, were not included in the calculations. 
Measurements were run in triplicate for each film. Two mechanical 
properties, namely, TS and % E/B were computed for the evaluation 
of the film. TS is the maximum stress applied to a point at which the 
film specimen breaks and was computed from the applied load at 
rupture as a mean of three measurements and cross sectional area 
of fractured film as described from the following equation. 
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In vitro release study 
A patch of 2 × 2 cm2size was cut and attached to a glass slide with a 
few drops of phosphate buffer (pH 6.8). This slide was kept at an angle 
of 45 °C in a 250 ml beaker containing 100 ml of phosphate buffer (pH 
6.8) solution. The beaker was kept in circulating water bath in which 
the temperature was maintained at 37 °C. A non-agitated system was 
selected to eliminate any effect of turbulence on the release rate. 
Samples were withdrawn periodically after removing the slide from 
the beaker. The solution was stirred with a glass rod and 5 ml of 
sample was withdrawn using a graduated pipette, whose tip was 
attached to a tube with glass wool (as a filter). The slide was quickly 
reintroduced into the beaker. 5 ml of the buffer was replaced 
immediately and the beaker was kept covered with a petridish to 
prevent evaporation of the fluid. The samples were taken after every 
10 min upto 90 min and analysed for drug contents.  
The withdrawn samples were analyzed spectrophotometrically at 
235.5 nm and 264.5 nm for  
With suitable dilution, samples were measured for absorbance using 
UV-Visible spectrophotometer 235.5 nm and 264.5 nm for HCZ and 
ATN respectively by using Shimadzu double beam ultra violet-visible 
spectrophotometer (UV-1700, Shimadzu Corporation, Tokyo, Japan). 
The release studies were conducted for three times and average was 
determined for HCZ and ATN [9, 10]. 
In vitro diffusion study 
In vitro diffusion study was performed by using modified franz 
diffusion cell across cellophane membrane. Phosphate buffer 
solution (PBS) of pH 6.8 was used as medium for diffusion study. 
Patches of dimension 1×1 cm2were placed on the membrane, which 
was placed between donor and receptor compartment of Franz 
diffusion cell. Cellophane membrane was brought in contact with 
PBS of pH 6.8 filled in receptor compartment. Temperature was 
maintained at 37 °C with stirring at 50 rpm using magnetic bead 
stirrer. 1 ml of sample was withdrawn from receptor compartment 
at pre-determined interval and was replaced with fresh PBS of pH 
6.8. With suitable dilution, samples were measured for absorbance 
using UV-Visible spectrophotometer 235.5 and 264.5 nm 
respectively for HCZ and ATN [11, 12]. 
Ex vivo permeability study 
The extent and rate of mucosal permeation of HCZ and ATN through 
the porcine buccal mucosa were carried out using Franz diffusion 
cell. The effective diffusion area was 1.8 cm2. The receptor 
compartment (40 ml) was filled with PBS, pH 6.8, and its 
temperature was maintained at 37±0.5 °C. 50 rpm stirring speed 
was applied using a magnetic stirrer to simulate buccal cavity 
environment. The patch of 1×1 cm2was applied under occlusion on 
the buccal mucosal surface of the goat fitted between the donor and 
receptor compartments of the diffusion cell. 5 ml of the sample from 
receptor medium was withdrawn at regular intervals and replaced 
immediately with an equal volume of PBS, pH 6.8. The amount of 
HCZ and ATN released into the receptor medium was quantified by 
using UV-Visible Spectrophotometer at 235.5 and 264.5 nm 
respectively against a blank [13, 14]. 
Kinetic analysis  
To analyse the mechanism of the drug release rate kinetics of the 
dosage form, the data obtained were fitted into % cumulative drug 
release (CDR) vs time for Zero order kinetics, Log % CDR remaining 
vs time for First order kinetics, % CDR vs Square root of time for 
Higuchi model and Log % CDR vs Logt for Korsmeyer model were 
plotted to obtain R2 values [15]. 
Stability study 
Stability testing of drug products begins as a part of drug discovery 
and ends with the demise of the compound or commercial product. 
Food and Drug Administration (FDA) and International conference 
of Harmonization (ICH) specifies the guidelines for stability testing 
of new drug products, as a technical requirement for the registration 
of pharmaceuticals for human use. The ICH Tripartite Guidelines 
have established that long term stability testing should be done at 
25 °C/60 % (Relative Humidity) RH; stress testing should be done at 
40 °C/75 % RH for 6 mo. If significant change occurs at these stress 
conditions, then the formulation should be tested at an intermediate 
condition i.e. 30 °C/75 % RH. In the present study stability studies 
were carried out at two different temperatures i.e., refrigeration 
temperature (2±8 °C) and room temperature (25±30 °C) [14, 15]. 
RESULTS AND DISCUSSION 
Compatibility studies 
IR studies were carried out for pure drugs and excipients which 
were used in formulations to determine the interaction between 
drug and polymers The IR spectra are given in the fig. 1 a,b,c and d. 
The spectral values for the drugs were compared with reference 
standard sample spectra. The IR spectrum of the HCZ showed the 
characteristic peaks at 3362.04 cm-1 (NH stretching group), 1604.83 
cm-1 (C-C stretching group), 1244.13 cm-1 (SO2 stretching group) and 
2690 cm-1(-CH2 group). The IR spectrum of the ATN showed the 
characteristic peaks at 1650 cm-1 (O= C-NH2 group), 2880-2900 cm-1 
(CH group), 2916-2936 cm-1 (CH2 group), 2850 cm-1 (CH3 group), 
1640-1610 cm-1 (C=C group), 3200-3550 cm-1 (-OH group). The 
spectra of formulations showed presence of peaks in the region of 
characteristic peaks of drugs confirmed the absence of interaction 
between the drugs and excipients used in the formulation. 
 
 
Fig. 1a: FTIR spectra of pure HCZ 
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Fig. 1b: FTIR spectra of pure ATN 
 
 
Fig. 1c: FTIR spectra of of HCZ, ATN and F3 formulation 
 
 
Fig. 1d: FTIR spectra of of HCZ, ATN and F4 formulation 
 
Physico-chemical evaluation of prepared buccal patches 
All formulated patches were found to be smooth in texture and 
transparent. The individual weight of 3 formulations of each type 
were determined and the average weight was calculated. It was 
observed that the weight of the patches in each formulation was 
found to be uniform. The thickness of the patches of each 
formulation was determined using micrometer screw gauge. It was 
observed that the thickness of all patch samples were found to be 
uniform in each formulation. The patches with increased polymer 
content showed a marginal increase in thickness. The folding 
endurance was determined as per the procedure mentioned in the 
methodology. It was found that all the formulations showed good 
folding endurance greater than 300. The surface pH of the patches 
was also determined and observed that the surface pH of each 
patch was found between 6.15 to 6.66 and which means that they 
may have less potential to irritate the buccal mucosa, as a result 
patches will be compatible to mucosa. The percentage drug 
content of all formulations was found to be in the range of 97-99 
%. Among the formulations prepared, it was observed that FC 
takes longer time to disintegrate since it contains Carbopol 934 
and HPMC which is highly viscous at increased concentration [16, 
17]. The results for all formulations and the average of 3 
determinations are given in table 2. 
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Table 2: Results of physic-chemical parameters 
Formulation code Weight (mg)* Thickness (mm)* Surface pH Folding endurance Drug content (%)* 
FA 1 39±0.04 0.54±0.02 6.3 326 30±0.10 
 2 38±0.03 0.56±0.03 6.2 314 35±0.12 
 3 40±0.04 0.57±0.02 6.3 339 40±0.13 
FB 1 45±0.02 0.53±0.04 6.1 348 40±0.04 
 2 46±0.05 0.53±0.02 6.2 330 45±0.06 
 3 48±0.06 0.54±0.05 6.3 335 60±0.06 
FC  1 48±0.02 0.58±0.02 6.4 331 45±0.07 
  2 46±0.04 0.56±0.03 6.6 333 50±0.07 
  3 47±0.06 0.55±0.01 6.3 350 60±0.07 
FD  1 49±0.03 0.54±0.03 6.2 310 30±0.08 
  2 48±0.04 0.51±0.04 6.1 315 35±0.08 
 3 44±0.02 0.59±0.02 6.3 325 45±0.12 
*n=3, SD-standard deviation, F-formulation 
 
Measurement of swelling index 
The hydration and swelling behavior of the polymer was reported to 
be crucial for its bio adhesive character because the former is 
necessary to initiate intimate contact of the patch with the mucosal 
surface. The adhesion increases with the degree of hydration until a 
point where over hydration leads to an abrupt drop in adhesive 
strength due to disentanglement at the polymer tissue interface. The 
rate and the extent of patch hydration and swelling also affects the 
patch adhesion and consequently the drug release from the patch. 
Studies have shown that excessive hydration can lead to weakening 
of the adhesive bond due to dilution of functional groups responsible 
for the adhesive interaction between the bio adhesive patch and 
mucosa. It was found that the increase in swelling of patches 
formulated with Carbopol 934 and HPMC was more compared to 
other formulations. This result may be attributed to complete 
penetration of solvent and high viscosity of the carbopol 934. The 
obtained results showed that the swelling front erosion was 
comparably slower in formulation batch with Carbopol 934 and 
HPMC due to their marked viscosity properties. Hence the 
formulation provides sustained release of drug. The poor solubility 
of SA limits the swelling of the patch [17] (fig. 2). 
 
 
Fig. 2: Swelling index, (All the values were calculated as mean±standard deviation; n=3) 
 
Bioadhesive strength 
In vitro mucoadhesive strength was determined on the modified 
balance to measure the force of adhesion (N) required to detach the 
tablet. From the overall study it was concluded that the 
mucoadhesive strength of polymers depend on their structure and 
other physicochemical properties. As the mucoadhesive polymer 
mixture concentration increased, the mucoadhesive strength and 
force of adhesion increased. Very strong mucoadhesion could 
damage the epithelial lining of the buccal mucosa. Among all the 
formulations FC (Carbopol 934 and HPMC) has higher mucoadhesive 
strength and higher the force required to detach from mucosa. 
Therefore FC patches can be considered satisfactory for maintaining 
them in the oral cavity for 8h. Among FA and FD maximum 
bioadhesion was observed for SA patches [18, 19]. 
Tensile strength (TS) and percentage elongation (E/B) 
The TS gives an indication of the strength and elasticity of the patch. A 
weak and soft polymer is characterized by a low TS and E/B, a hard 
and brittle polymer shows a moderate TS and low E/B, a soft and 
tough polymer is characterized by a moderate TS and high E/B 
whereas a hard and tough polymer shows a high TS and E/B. The 
results showed that, among the formulation FA to FD, TS and E/B 
increased with the increase in the percentage of polymers. 
Formulations FD (with CP and NaCMC) and FC (Carbopol 934 and 
HPMC) showed high Tensile strength and % E/B than FA (with SA and 
HPMC) and FB (HPMC and NaCMC) which indicated that FC and FD 
gives good tensile strength to buccal patches which are tough and 
strong enough for use compared to FA and FB. In case of formulations 
FA and FD, FA (SA and HPMC) at higher concentration showed TS and 
E/B greater compared to formulation FD (CP and NaCMC), indicated 
that the inclusion of CP decreased the tensile strength. This indicates 
that the presence of water soluble polymers tend to make the polymer 
softer and less tough and therefore poor TS and E/B [19] (table 3). 
In vitro release studies 
Amongst the formulations FC2 containing carbopol 934 and HPMC 
(2:3) released the drug in sustained form i. e, 95 % at 8 h since 
carbopol 934 at higher concentration created a high viscosity gel 
barrier for drug diffusion. Increased concentrations of NaCMC 
resulted faster drug release. This result was attributed to water 
soluble polymer NaCMC, results in increased wettability and 
penetration of water into the patch matrices and hence increased 
diffusion of the drug [20] (fig. 3 and 4). 
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Table 3: Tensile strength and % elongation of different formulations 
Formulation code Tensile strength (Kg/mm2) % Elongation  
FA 1 0.89±0.01 37.5±0.03 
 2 0.79±0.02 39.1±0.04 
 3 0.85±0.03 55.0±0.05 
FB 1 0.65±0.02 19.0±0.02 
 2 0.60±0.02 20.0±0.01 
 3 0.62±0.01 25.7±0.03 
FC 1 1.15±0.03 90.1±0.01 
 2 1.17±0.03 89.7±0.04 
 3 1.19±0.02 85.2±0.05 
FD 1 0.95±0.01 57.0±0.01 
 2 0.98±0.01 59.0±0.01 
 3 0.94±0.02 60.0±0.04 
 n=3, SD-standard deviation, F-formulation, %-percentage 
 
 
Fig. 3: In vitro drug release of HCZ, (Results are expressed as as 
mean±standard deviation; n=3) 
 
 
Fig. 4: In vitro drug release of ATN, (Results are expressed as as 
mean±standard deviation; n=3) 
 
 
Fig. 5: In vitro diffusion of HCZ, (Results are expressed as as 
mean±standard deviation; n=3) 
 
Fig. 6: In vitro diffusion of ATN, (Results are expressed as as 
mean±standard deviation; n=3) 
 
 
Fig. 7: In vitro drug permeation of HCZ, (Results are expressed 
as as mean±standard deviation; n=3) 
 
 
Fig. 8: In vitro drug permeation of ATN, (Results are expressed 
as as mean±standard deviation; n=3) 
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In vitro diffusion studies 
It was found that in FC 2 formulation containing carbopol 934 and 
HPMC (2:3) was found to be comparable with the in vitro diffusion 
study data and hence indicated a good diffusion coefficient which is 
essential for all such drugs which are formulated for the purpose of 
sustained formulations. Hence FC 2 was found to be better amongst 
the formulation [21]. This may be attributed due to increasing 
concentration of polymers [21] (fig. 5 and 6). 
Ex vivo permeation studies 
It was observed that, as the polymer content increased, the % 
drug permeation decreased. The formulation containing 
Carbopol 934 and HPMC showed better permeation compared to 
all other formulations. It was found that the results obtained in 
ex vivo study indicated that drug has the better ability to cross 
the buccal barrier at a faster rate and hence the delivery system 
has the potential of overcoming the drawbacks associated with 
presently available tablet formulations in the market (fig. 7 and 
8). 
Kinetic analysis  
In order to determine the release mechanism that provides the best 
description to the pattern of drug release, the in vitro release data 
were fitted to Zero order, First order, and Higuchi model. The 
release data were also kinetically analysed using the Korsmeyer-
Peppas model. The data were processed for regression analysis 
using MS–EXCEL statistical function [22] (table 4). 
  
Table 4: Kinetic release of different formulations 
Formulation code Zero order R2 First order R2 Higuchi model R2 Korsmeyer peppas model N R2 
FA 1 0.9736 0.9963 0.7122 0.9656 0.4535 
 2 0.9798 0.9950 0.6968 0.9776 0.4578 
 3 0.9798 0.9866 0.6977 0.9780 0.4598 
FB 1 0.9657 0.9933 0.6736 0.9638 0.4637 
 2 0.9783 0.9960 0.6923 0.9778 0.4789 
 3 0.9702 0.9897 0.6886 0.9734 0.4739 
FC 1 0.9766 0.9933 0.7210 0.9938 0.4761 
 2 0.9826 0.9976 0.6825 0.9866 0.4839 
 3 0.9839 0.9878 0.6999 0.9880 0.4817 
FD 1 0.9656 0.9945 0.6856 0.9333 0.4839 
 2 0.9742 0.9913 0.6890 0.9413 0.4981 
 3 0.9668 0.9955 0.6843 0.9766 0.4937 
F-formulation 
 
By using Korsmeyer-Peppas model, if n= 0.45 it is Case-1 or Fickian 
diffusion, 0.45<n>0.89 is for anomalous behavior or nonfickian 
transport, n= 0.89 for Case 11 transport, and n>0.89 for Super Case 
11 transport. Fickian release usually occurs by molecular diffusion 
of the drug due to a chemical potent gradient. Case 11 relaxation 
release is the drug transport mechanism associated with stresses 
and state transition in hydrophilic glassy polymers, which swell in 
water or biological fluids. This term also includes polymer 
disentanglement and erosion. In the present investigation, the 
release from the polymers followed anomalous behavior or non-
fickian transport. As a result the combination of diffusion and 
erosion was the mechanism followed by the formulations as the ‘n’ 
values ranged from 0.4535 to 0.4937 as per Korsmeyer-Peppas 
model, which in turn justified suitability of polymers for the 
preparation of buccal patches [22] 
Stability studies 
Stability testing was carried out for all the formulations for a period 
of eight weeks. All the formulations were evaluated with respect to 
physical appearance, drug content, surface pH, swelling index and in 
vitro drug release. The results of stability studies of HCZ and ATN 
buccal patches showed no significant change with respect to 
physical appearance, drug content, surface pH, swelling index and in 
vitro drug release at the end of eight weeks when stored in 
refrigeration temperature (2±8 °C) and room temperature (25±30 
°C). Ageing did not alter the drug release profiles of any of the 
patches significantly till the end of the storage period. Buccal 
patches were found to be physically and chemically stable. 
CONCLUSION 
Sustained release patch may open a new horizon in buccal drug 
delivery system. In the present investigation, an attempt was made 
to improve the systemic bioavailability, avoidance of pre-systemic 
elimination within the GI tract and optimize therapeutic efficacy of 
the selected drugs by designing carefully mucoadhesive buccal 
patches for control release of HCZ and ATN. HCZ and ATN are 
available in combination in conventional tablet form in a market and 
are effective in the combination for the treatment of hypertension. 
Hence this drug combination will benefit from formulation into 
mucoadhesive buccal patches by avoiding first pass metabolism and 
therefore improvement in bioavailability and also improves patient 
compliance by reducing dosing frequency. 
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